DK1503800T3 - Behandling og forebyggelse af vævsskade associeret med forøget C-reaktiv-protein produktion - Google Patents
Behandling og forebyggelse af vævsskade associeret med forøget C-reaktiv-protein produktionInfo
- Publication number
- DK1503800T3 DK1503800T3 DK03727670.6T DK03727670T DK1503800T3 DK 1503800 T3 DK1503800 T3 DK 1503800T3 DK 03727670 T DK03727670 T DK 03727670T DK 1503800 T3 DK1503800 T3 DK 1503800T3
- Authority
- DK
- Denmark
- Prior art keywords
- reactive protein
- prevention
- treatment
- increased
- tissue damage
- Prior art date
Links
- 108010074051 C-Reactive Protein Proteins 0.000 title abstract 5
- 102100032752 C-reactive protein Human genes 0.000 title abstract 5
- 230000002265 prevention Effects 0.000 title 1
- 230000000451 tissue damage Effects 0.000 title 1
- 231100000827 tissue damage Toxicity 0.000 title 1
- 230000014616 translation Effects 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 7
- 108010045517 Serum Amyloid P-Component Proteins 0.000 abstract 2
- 102100036202 Serum amyloid P-component Human genes 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0211136.7A GB0211136D0 (en) | 2002-05-15 | 2002-05-15 | Treatment and prevention of tissue damage |
| PCT/GB2003/002096 WO2003097104A1 (en) | 2002-05-15 | 2003-05-14 | Treatment and prevention of tissue damage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1503800T3 true DK1503800T3 (da) | 2010-02-01 |
Family
ID=9936726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03727670.6T DK1503800T3 (da) | 2002-05-15 | 2003-05-14 | Behandling og forebyggelse af vævsskade associeret med forøget C-reaktiv-protein produktion |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7615543B2 (enExample) |
| EP (1) | EP1503800B1 (enExample) |
| JP (2) | JP2005531559A (enExample) |
| AT (1) | ATE446761T1 (enExample) |
| AU (1) | AU2003234000B8 (enExample) |
| CA (1) | CA2485852C (enExample) |
| DE (1) | DE60329839D1 (enExample) |
| DK (1) | DK1503800T3 (enExample) |
| ES (1) | ES2333522T3 (enExample) |
| GB (1) | GB0211136D0 (enExample) |
| WO (1) | WO2003097104A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0211136D0 (en) * | 2002-05-15 | 2002-06-26 | Univ London | Treatment and prevention of tissue damage |
| CN101845009B (zh) | 2002-07-29 | 2012-10-03 | 卡达克斯药物公司 | 用于抑制和改善疾病的类胡萝卜素结构类似物 |
| PT1596880E (pt) | 2002-12-23 | 2011-06-06 | Univ Rice William M | Métodos e composições para suprimir a diferenciação de fibrócitos |
| US7763256B2 (en) | 2002-12-23 | 2010-07-27 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation |
| US8012472B2 (en) | 2002-12-23 | 2011-09-06 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes |
| GB0313386D0 (en) * | 2003-06-10 | 2003-07-16 | Univ London | Treatment of disease |
| US20070265196A1 (en) * | 2004-01-21 | 2007-11-15 | Medvet Science Pty., Ltd. | Method of Modulating Pro-Inflammatory and Inflammatory Activity Mediated by C-Reactive Protein |
| EP1582527A1 (en) * | 2004-03-31 | 2005-10-05 | Ciba SC Holding AG | Synthesis of phosphorus based ligands |
| CA2654440C (en) * | 2005-06-06 | 2013-09-03 | Girish J. Kotwal | Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury |
| ES2409756T3 (es) | 2006-12-04 | 2013-06-27 | Promedior, Inc. | Combinación de SAP y de enalapril para su uso en tratamiento de trastornos fibróticos o fibroproliferativos |
| US8497243B2 (en) | 2007-07-06 | 2013-07-30 | Promedior, Inc. | Methods and compositions useful in the treatment of mucositis |
| US9884899B2 (en) | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
| EP2405929B1 (en) | 2009-03-11 | 2018-06-06 | Promedior Inc. | A sap polypeptide for use in the treatment of autoimmune disorders and graft vs host disease |
| CA2754961C (en) | 2009-03-11 | 2018-04-10 | Promedior, Inc. | Treatment and diagnostic methods for hypersensitive disorders |
| UA110323C2 (en) | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
| EP2987803B1 (en) | 2009-06-17 | 2018-08-29 | Promedior Inc. | Sap variants and their use |
| US8674027B2 (en) | 2009-09-18 | 2014-03-18 | Dow Global Technologies Llc | Powdered thermoplastic polyolefin elastomer composition for slush molding processes |
| WO2011155956A1 (en) | 2010-06-08 | 2011-12-15 | Dow Global Technologies Llc | Polyolefin elastomer composition for artificial leather applications |
| US20150087576A1 (en) * | 2011-12-14 | 2015-03-26 | The Texas A&M University System | Compositions associated with and methods of managing neutrophil movement using serum amyloid p (sap) |
| EP2890300B1 (en) | 2012-08-31 | 2019-01-02 | Kenji Suzuki | Supervised machine learning technique for reduction of radiation dose in computed tomography imaging |
| EP2957563A1 (en) * | 2014-06-19 | 2015-12-23 | Pentracor GmbH | Separation material comprising phosphoryl choline derivatives |
| GB202002299D0 (en) * | 2020-02-19 | 2020-04-01 | Pentraxin Therapeutics Ltd | Agents for use in the treatment of tissue damage |
| WO2021197371A1 (zh) * | 2020-03-31 | 2021-10-07 | 南京金斯瑞生物科技有限公司 | 一种含有刚性连接子的生物偶联物 |
| WO2022178594A1 (en) * | 2021-02-25 | 2022-09-01 | Baker Heart and Diabetes Institute | C-reactive protein inhibitors |
| GB202111866D0 (en) | 2021-08-18 | 2021-09-29 | Ucl Business Plc | Prodrugs for use in the treatment of tissue damage |
| KR20230060368A (ko) * | 2021-10-27 | 2023-05-04 | 솔브레인 주식회사 | 환형 포스핀 화합물의 제조방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4640913A (en) | 1983-01-10 | 1987-02-03 | American Cyanamid Company | Phosphocholine derivatives having antihypertensive action |
| IL84252A (en) | 1987-10-23 | 1994-02-27 | Yissum Res Dev Co | Phospholipase inhibiting compositions |
| US5811568A (en) | 1992-10-08 | 1998-09-22 | Shaman Pharmaceuticals, Inc. | Process for the preparation of mono- and bis(phosphocholine) derivatives which have antifungal activity |
| US5681829A (en) | 1992-10-08 | 1997-10-28 | Shaman Pharmaceuticals, Inc. | Class of phosphocholine derivatives having antifungal activity |
| JP4524846B2 (ja) | 2000-04-20 | 2010-08-18 | 日油株式会社 | 化粧料 |
| US6764826B2 (en) | 2000-06-08 | 2004-07-20 | Board Of Regents, The University Of Texas System | Inhibitors of C-reactive protein induced inflammation |
| US7390795B2 (en) * | 2000-12-18 | 2008-06-24 | Pentraxin Therapeutics Limited | Treatment and prevention of tissue damage |
| JP4472333B2 (ja) | 2001-08-08 | 2010-06-02 | ペントラキシン セラピューティクス リミテッド | 好ましくないタンパク質群を患者の血漿から除去するための薬剤 |
| GB0211136D0 (en) * | 2002-05-15 | 2002-06-26 | Univ London | Treatment and prevention of tissue damage |
-
2002
- 2002-05-15 GB GBGB0211136.7A patent/GB0211136D0/en not_active Ceased
-
2003
- 2003-05-14 DE DE60329839T patent/DE60329839D1/de not_active Expired - Lifetime
- 2003-05-14 ES ES03727670T patent/ES2333522T3/es not_active Expired - Lifetime
- 2003-05-14 US US10/514,127 patent/US7615543B2/en not_active Expired - Fee Related
- 2003-05-14 DK DK03727670.6T patent/DK1503800T3/da active
- 2003-05-14 JP JP2004505099A patent/JP2005531559A/ja not_active Ceased
- 2003-05-14 EP EP03727670A patent/EP1503800B1/en not_active Expired - Lifetime
- 2003-05-14 WO PCT/GB2003/002096 patent/WO2003097104A1/en not_active Ceased
- 2003-05-14 AT AT03727670T patent/ATE446761T1/de not_active IP Right Cessation
- 2003-05-14 CA CA2485852A patent/CA2485852C/en not_active Expired - Fee Related
- 2003-05-14 AU AU2003234000A patent/AU2003234000B8/en not_active Ceased
-
2010
- 2010-02-04 JP JP2010022669A patent/JP2010174013A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010174013A (ja) | 2010-08-12 |
| CA2485852A1 (en) | 2003-11-27 |
| ATE446761T1 (de) | 2009-11-15 |
| GB0211136D0 (en) | 2002-06-26 |
| ES2333522T3 (es) | 2010-02-23 |
| AU2003234000B8 (en) | 2008-07-31 |
| DE60329839D1 (de) | 2009-12-10 |
| AU2003234000A1 (en) | 2003-12-02 |
| US7615543B2 (en) | 2009-11-10 |
| JP2005531559A (ja) | 2005-10-20 |
| WO2003097104A1 (en) | 2003-11-27 |
| EP1503800A1 (en) | 2005-02-09 |
| AU2003234000B2 (en) | 2008-06-05 |
| CA2485852C (en) | 2012-01-17 |
| EP1503800B1 (en) | 2009-10-28 |
| US20060019930A1 (en) | 2006-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1503800T3 (da) | Behandling og forebyggelse af vævsskade associeret med forøget C-reaktiv-protein produktion | |
| EA200801172A1 (ru) | Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения | |
| NO20062087L (no) | Bispesifikt antistoff som substituerer for funksjonelle proteiner | |
| EA200801521A1 (ru) | Лиганды, которые обладают специфичностью связывания к vegf и/или egfr, и способы их применения | |
| IL311603B2 (en) | Bispecific antibodies and compounds containing them for cancer treatment | |
| ATE515514T1 (de) | Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien | |
| DE602004025101D1 (de) | Humane anti-humane cd3-bindungsmoleküle | |
| ES2534294T3 (es) | Métodos para tratar la preeclampsia | |
| NO20083785L (no) | Funksjonelle antistoffer | |
| DE60331329D1 (de) | Kristallstruktur des aurora-2 proteins und dessen bindungstaschen | |
| WO2006020060A3 (en) | Iap binding compounds | |
| DE69942578D1 (de) | Bifunktionelle moleküle sowie darauf basierende therapien. | |
| DK1742966T3 (da) | Antistoffer og molekyler afledt deraf som binder til STEAP-1 proteiner | |
| EA200701211A1 (ru) | Полипептиды, которые связываются с br3, и их применение | |
| DK1766093T3 (da) | Antistoffer mod clostridium difficile-toksiner og anvendelse deraf | |
| NO20070062L (no) | RAGE-fusjonsproteiner og fremgangsmater for anvendelse av samme | |
| EA201001734A1 (ru) | Улучшенные связывающие молекулы на основе фибронектина и их применение | |
| EA200970694A1 (ru) | ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ | |
| DK1912674T3 (da) | Bispecifikt enkeltkæde FV-antistofmolekyle og fremgangsmåder til anvendelse deraf | |
| BR112022006817A2 (pt) | Anticorpos direcionados a flt3 e uso dos mesmos | |
| WO2006069186A3 (en) | Small molecule bcl-xl/bcl-2 binding inhibitors | |
| WO2002050122A3 (en) | Means for the diagnosis and therapy of ctcl | |
| ATE417605T1 (de) | Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität | |
| EA200602047A1 (ru) | Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака | |
| WO2006129843A3 (en) | Bispecific capturing molecule |